Immunotherapy Drugs

World Market Report

MCP12540

EXECUTIVE ENGAGEMENTS

POOL

5894
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

943
Interactions with Platform & by Email

PARTICIPANTS

177
Unique # Participated

VALIDATIONS

38
Responses Validated*

COMPANIES

44
Responses Validated*
* Login for a full stack data experience

DATE

MAR 2023

TABLES

123

PAGES

193

EDITION

8

PRICE

USD 4950

CODE

MCP12540


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Immunotherapy Drugs Market to Reach $498.4 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Immunotherapy Drugs estimated at US$238.4 Billion in the year 2022, is projected to reach a revised size of US$498.4 Billion by 2030, growing at aCAGR of 9.7% over the period 2022-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$229.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Checkpoint Inhibitors segment is readjusted to a revised 10.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $72.7 Billion, While China is Forecast to Grow at 9% CAGR
The Immunotherapy Drugs market in the U.S. is estimated at US$72.7 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$84.9 Billion by the year 2030 trailing a CAGR of 9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

SELECT PLAYERS

AbbVie, Inc.; Amgen, Inc.; AstraZeneca PLC; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG

SEGMENTS

» Type (Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins, Other Types) » Therapeutic Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapeutic Areas) » End-Use (Hospitals, Clinics, Other End Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
Immunotherapy Drugs – Global Key Competitors Percentage Market Share in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Immunotherapy Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
World Recent Past, Current & Future Analysis for Immunotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Immunotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Immunotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Interferons & Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Interferons & Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Interferons & Interleukins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Autoimmune & Inflammatory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Autoimmune & Inflammatory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Autoimmune & Inflammatory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
World Recent Past, Current & Future Analysis for Other End Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World Historic Review for Other End Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
World 16-Year Perspective for Other End Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
UNITED STATES
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
USA Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
USA Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
USA 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
USA Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
USA Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
USA 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
USA Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
USA Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
USA 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
CANADA
Canada Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Canada Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Canada 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Canada Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Canada Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Canada 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Canada Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Canada Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Canada 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
JAPAN
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Japan Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Japan Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Japan 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Japan Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Japan Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Japan 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Japan Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Japan Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Japan 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
CHINA
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
China Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
China Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
China 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
China Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
China Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
China 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
China Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
China Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
China 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
EUROPE
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Europe Historic Review for Immunotherapy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Immunotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Europe Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Europe Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Europe Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Europe 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
FRANCE
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
France Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
France Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
France 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
France Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
France Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
France 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
France Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
France Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
France 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
GERMANY
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Germany Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Germany Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Germany 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Germany Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Germany Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Germany 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Germany Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Germany Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Germany 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
ITALY
Italy Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Italy Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Italy 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Italy Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Italy Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Italy 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Italy Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Italy Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Italy 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
UNITED KINGDOM
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
UK Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
UK Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
UK 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
UK Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
UK Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
UK 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
UK Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
UK Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
UK 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of Europe Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Rest of Europe 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Rest of Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of Europe Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Rest of Europe 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Rest of Europe Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of Europe Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Rest of Europe 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
ASIA-PACIFIC
Immunotherapy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Asia-Pacific Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Asia-Pacific 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Asia-Pacific Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Asia-Pacific 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Asia-Pacific Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Asia-Pacific 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of World Historic Review for Immunotherapy Drugs by Type - Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Rest of World 16-Year Perspective for Immunotherapy Drugs by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Checkpoint Inhibitors, Interferons & Interleukins and Other Types for the Years 2014, 2023 & 2030
Rest of World Recent Past, Current & Future Analysis for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of World Historic Review for Immunotherapy Drugs by Therapeutic Area - Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Rest of World 16-Year Perspective for Immunotherapy Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Other Therapeutic Areas for the Years 2014, 2023 & 2030
Rest of World Recent Past, Current & Future Analysis for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of World Historic Review for Immunotherapy Drugs by End-Use - Hospitals, Clinics and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Rest of World 16-Year Perspective for Immunotherapy Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End Uses for the Years 2014, 2023 & 2030

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com